Navigation Links
PDI Reports 2009 Fourth Quarter and Full Year Financial Results
Date:3/4/2010

 In 2009:

  • A non-cash asset impairment charge of $18.1 million (reflected in Q4 and full year 2009 results) related to the carrying value of our Pharmakon business unit goodwill and intangibles. This charge is the result of the Company's annual assessment of goodwill and an indication of impairment of our intangibles which arose in the fourth quarter of 2009.  The most recent assessment was heavily influenced by the recent performance of Pharmakon, adverse industry dynamics, the general adverse economic environment and reduced valuations of comparable companies.

  • Facilities realignment charges of $5.7 million in the fourth quarter of 2009 and $8.7 million for the full year 2009, related to the downsizing of space at our former Company headquarters and TVG business unit and the fourth quarter relocation of Company's corporate headquarters to Parsippany, NJ.


'/>"/>
SOURCE PDI, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
2. Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results
3. Volcano Reports 44 Percent Increase in Fourth Quarter Revenues
4. China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results
5. WorldHeart Reports 2009 Financial Results
6. Questcor Reports Solid Fourth Quarter Results
7. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
8. CRF Health Reports Record Growth and Earnings
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), announced ... (NDA) to the U.S. Food and Drug Administration ... approval for Xibrom QD,as a treatment for inflammation, ... ophthalmic solution), Xibrom is a topical non-steroidal ...
... Will Fund 20 Percent of Cost for New Hospital, ... that it has reached its $50 million Capital Campaign,goal, ... ever,undertaken. A recent gift of $500,000 from the Stephen ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
... 20 Today URAC called for,comments on ... Health Web,Site, HIPAA Privacy (Business Associate and ... Covered Entity) accreditation programs.,URAC is seeking input ... care management organizations and health plans. The,deadline ...
... MCG Capital,Corporation (Nasdaq: MCGC ) today announced ... the acquisition of Gould & Lamb, LLC by ABRY,Partners ... company that is unique to,the workers, compensation industry. The ... workers, compensation industry,since 2001. Having completed in excess of ...
... ... Nataline Sarkisyan ... GLENDALE, Calif., Dec. 20 In a stunning turn around,insurance ... California Nurses Association/National Nurses Organizing Committee,helped to generate, and agreed ...
... of Howard G. Smith,announces a September 4, 2007, ... in,the securities class action lawsuit filed on behalf ... Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or the "Company")(Nasdaq: THLD ... (the "Class Period"), including purchasers in Threshold,s,February 4, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2Health News:CIGNA Capitulates to Patient Revolt 2Health News:CIGNA Capitulates to Patient Revolt 3Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: